Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
| AbbVie (NYSE: ABBV) | Delayed: 294.89 +4.10 (1.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $290.79 | 52 Week High | $68.12 | |||
| Open | $292.00 | 52 Week Low | $50.71 | |||
| Day High | $298.74 | P/E | 63.97 | |||
| Day Low | $291.01 | EPS | $4.61 | |||
| Volume | 6,898,158 | |||||
| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 253.62 +3.97 (1.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $249.65 | 52 Week High | $333.65 | |||
| Open | $255.39 | 52 Week Low | $223.02 | |||
| Day High | $258.73 | P/E | 32.47 | |||
| Day Low | $251.19 | EPS | $7.81 | |||
| Volume | 1,332,669 | |||||
